Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Genes (Basel) ; 12(6)2021 06 16.
Article in English | MEDLINE | ID: mdl-34208492

ABSTRACT

Targeting DNA repair proteins with small-molecule inhibitors became a proven anti-cancer strategy. Previously, we identified an inhibitor of a major protein of homologous recombination (HR) RAD51, named B02. B02 inhibited HR in human cells and sensitized them to chemotherapeutic drugs in vitro and in vivo. Here, using a medicinal chemistry approach, we aimed to improve the potency of B02. We identified the B02 analog, B02-isomer, which inhibits HR in human cells with significantly higher efficiency. We also show that B02-iso sensitizes triple-negative breast cancer MDA-MB-231 cells to the PARP inhibitor (PARPi) olaparib.


Subject(s)
Antineoplastic Agents/pharmacology , Enzyme Inhibitors/pharmacology , Homologous Recombination/drug effects , Quinazolinones/pharmacology , Rad51 Recombinase/antagonists & inhibitors , Antineoplastic Agents/chemistry , Binding Sites , Cell Line, Tumor , Cell Proliferation/drug effects , Drug Synergism , Enzyme Inhibitors/chemistry , Humans , Molecular Docking Simulation , Phthalazines/pharmacology , Piperazines/pharmacology , Protein Binding , Quinazolinones/chemistry , Rad51 Recombinase/chemistry , Rad51 Recombinase/metabolism
2.
Methods ; 39(1): 50-5, 2006 May.
Article in English | MEDLINE | ID: mdl-16774835

ABSTRACT

Amyloids and prions represent aggregates of misfolded proteins, which consist of protein polymer fibrils with cross-beta sheet structure. Understanding of their occurrence and role is developing rapidly. Initially, they were found associated with mammalian diseases, mainly of neurodegenerative nature. Now they are known to relate to a range of non-disease phenomena in different species from mammals to lower eukaryotes. Uncovering new prion- and amyloid-related processes may be helped greatly by a procedure for purification of amyloid polymers. Studies of growth and propagation of these polymers require methods for determination of their size. Here, we describe such methods. They rely on the treatment with cold SDS or Sarcosyl detergents, which do not dissolve amyloids, but solubilize almost all non-amyloid complexes and associations between amyloid fibers. This allows purifying amyloids by centrifugation in the presence of these detergents. The size of amyloid polymers may be analyzed by electrophoresis in agarose gels containing SDS. Two procedures are described for determining the proportion between polymers and monomers of a particular protein using polyacrylamide gels.


Subject(s)
Amyloid/analysis , Amyloid/isolation & purification , Prions/analysis , Prions/isolation & purification , Centrifugation , Detergents/chemistry , Electrophoresis, Agar Gel , Electrophoresis, Polyacrylamide Gel , Peptide Termination Factors , Saccharomyces cerevisiae/chemistry , Saccharomyces cerevisiae Proteins/analysis , Saccharomyces cerevisiae Proteins/isolation & purification
3.
Genetics ; 172(2): 827-35, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16272413

ABSTRACT

The cytoplasmic [PSI+] determinant of Saccharomyces cerevisiae is the prion form of the Sup35 protein. Oligopeptide repeats within the Sup35 N-terminal domain (PrD) presumably are required for the stable [PSI+] inheritance that in turn involves fragmentation of Sup35 polymers by the chaperone Hsp104. The nonsense suppressor [PSI+] phenotype can vary in efficiency probably due to different inheritable Sup35 polymer structures. Here we study the ability of Sup35 mutants with various deletions of the oligopeptide repeats to support [PSI+] propagation. We define the minimal region of the Sup35-PrD necessary to support [PSI+] as amino acids 1-64, which include the first two repeats, although a longer fragment, 1-83, is required to maintain weak [PSI+] variants. Replacement of wild-type Sup35 with deletion mutants decreases the strength of the [PSI+] phenotype. However, with one exception, reintroducing the wild-type Sup35 restores the original phenotype. Thus, the specific prion fold defining the [PSI+] variant can be preserved by the mutant Sup35 protein despite the change of phenotype. Coexpression of wild-type and mutant Sup35 containing three, two, one, or no oligopeptide repeats causes variant-specific [PSI+] elimination. These data suggest that [PSI+] variability is primarily defined by differential folding of the Sup35-PrD oligopeptide-repeat region.


Subject(s)
Genetic Variation , Oligopeptides/chemistry , Oligopeptides/physiology , Prions/chemistry , Prions/physiology , Repetitive Sequences, Amino Acid , Saccharomyces cerevisiae Proteins/chemistry , Saccharomyces cerevisiae Proteins/physiology , Saccharomyces cerevisiae/chemistry , Saccharomyces cerevisiae/physiology , Base Sequence , Oligopeptides/genetics , Peptide Termination Factors , Phenotype , Plasmids , Prions/genetics , Protein Folding , Protein Structure, Tertiary/genetics , Repetitive Sequences, Amino Acid/genetics , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae Proteins/genetics , Sequence Deletion
4.
Genetics ; 160(1): 25-36, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11805042

ABSTRACT

Two cytoplasmically inherited determinants related by their manifestation to the control of translation accuracy were previously described in yeast. Cells carrying one of them, [PSI(+)], display a nonsense suppressor phenotype and contain a prion form of the Sup35 protein. Another element, [PIN(+)], determines the probability of de novo generation of [PSI(+)] and results from a prion form of several proteins, which can be functionally unrelated to Sup35p. Here we describe a novel nonchromosomal determinant related to the SUP35 gene. This determinant, designated [ISP(+)], was identified as an antisuppressor of certain sup35 mutations. We observed its loss upon growth on guanidine hydrochloride and subsequent spontaneous reappearance with high frequency. The reversible curability of [ISP(+)] resembles the behavior of yeast prions. However, in contrast to known prions, [ISP(+)] does not depend on the chaperone protein Hsp104. Though manifestation of both [ISP(+)] and [PSI(+)] is related to the SUP35 gene, the maintenance of [ISP(+)] does not depend on the prionogenic N-terminal domain of Sup35p and Sup35p is not aggregated in [ISP(+)] cells, thus ruling out the possibility that [ISP(+)] is a specific form of [PSI(+)]. We hypothesize that [ISP(+)] is a novel prion involved in the control of translation accuracy in yeast.


Subject(s)
Fungal Proteins/genetics , Nuclear Proteins , Protein Biosynthesis/physiology , Saccharomyces cerevisiae Proteins , Saccharomyces cerevisiae/genetics , Schizosaccharomyces pombe Proteins , Alleles , Chromosomes, Fungal , Culture Media/metabolism , Extrachromosomal Inheritance , Gene Expression Regulation, Fungal , Genes, Dominant , Guanidine/metabolism , Heat-Shock Proteins/physiology , Peptide Termination Factors , Prions/genetics , Saccharomyces cerevisiae/metabolism , Suppression, Genetic
SELECTION OF CITATIONS
SEARCH DETAIL
...